% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • jcal4uhealth jcal4uhealth Aug 18, 2014 11:20 AM Flag

    Sanofi to buy Synta Pharmaceutical

    This is why Anne Whitaker was announced as CEO. Sanofi is being very aggressive with taking over small molecules. It will be announce very soon, not sure what the number is but it will be a huge premium.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Lets wait and see if Whitaker rents or buys in Lexington. If she only rents a condo then we know a sale is coming. IMHO

    • NTA) today announced that Anne Whitaker will join the Company as President, Chief Executive Officer and a member of the Company's Board of Directors effective September 2, 2014. Ms. Whitaker has more than 20 years of experience in the pharmaceutical industry, principally at GlaxoSmithKline and Sanofi including, most recently, the role of President, North America Pharmaceuticals, at Sanofi.

      "It is with great pleasure that the Board welcomes Anne Whitaker as Synta's new Chief Executive Officer," said Keith Gollust, Chairman of the Board of Synta. "Anne brings a wealth of experience to Synta, gained over a distinguished career in executive roles with two of the world's top pharmaceutical companies. Her knowledge and experience in business strategy, product development, regulatory affairs, leadership and organizational development and commercialization will be invaluable to the Company as we continue to advance ganetespib through late stage development."

      "Synta presents an exciting opportunity defined by a late stage product, ganetespib, that has shown promising activity in multiple indications and a pre-clinical program, HDC, that has significant potential to generate new drug candidates." said Ms. Whitaker. "I am excited to join the very talented and dedicated team at Synta at this important time in the Company's evolution. I look forward to working with this team to build a world-class global oncology and immunology business that delivers improved health to patients, innovative treatment solutions to healthcare providers and value to shareholders."
      The last paragraph states SNTA's and Whitaker's goal.........."world-class global oncology and immunology business".SNTA is not looking to be bought out.Their plan is to grow the business which is to create greater value than a buyout

      Sentiment: Strong Buy

    • And how do you have info of this?

      Sentiment: Buy

0.343+0.072(+26.61%)Jul 22 4:00 PMEDT